Harmony Biosciences Holdings is a holding company. Through its subsidiary, Harmony Biosciences, LLC, Co. is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological disorders. Co.'s product, WAKIX (pitolisant), is a molecule with a mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors. WAKIX has been approved for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. Also, WAKIX has been approved for the treatment of cataplexy in adult patients with narcolepsy. We show 15 historical shares outstanding datapoints in our HRMY shares outstanding history coverage, used to compute HRMY market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing HRMY market cap history over the course of time is important for investors
interested in comparing HRMY's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of HRMY versus a peer is one thing; comparing
HRMY market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like HRMY can fluctuate over the course of history.
With this page we aim to empower investors researching HRMY by allowing them to research the HRMY market cap history. |
Free HRMY Email Alerts:
Video: The Importance of Market Cap
